Mifepristone Abortion Pill: Severe Side Effects and FDA Scrutiny

Study Reveals Increased Risks of Mifepristone

• 💡 A new study by the Epics and Public Policy Center (EPC) indicates that the abortion pill Mifepristone has a 22 times greater rate of serious health risks than stated on the FDA-approved label.
• 🎯 The study analyzed nearly 900,000 prescribed abortions from 2017 to 2023, contrasting with the FDA's label data from approximately 31,000 claims.
• ⚠️ More than 1 in 10 patients taking Mifepristone risk severe side effects, including infections leading to sepsis or hemorrhaging requiring blood transfusions.
• 🏥 Approximately half of patients experiencing adverse events may require emergency room visits or hospitalization.

Criticisms of FDA's Oversight

• 📉 Senator Josh Hawley is calling out FDA Commissioner Marty Makary for slow action despite new data on Mifepristone's risks.
• 🚫 Makary admitted in an interview that he had not yet studied the new data, stating he had "no plans to take action on Mifepristone."
• ⚖️ The EPC study found nearly 11% severe adverse events, compared to less than 0.5% reported by the FDA.
• 🗣️ Critics, including Jamie Brian Hall from the EPC, argue the FDA has failed miserably in its responsibility to protect women from the drug's risks.

Loosened Safeguards and Calls for Action

• 📜 Lawmakers are urging the FDA to reinstate protocols that were in place when Mifepristone was approved in 2000.
• 📬 Current protocols allow women to receive the pills by mail after filling out a questionnaire, a stark contrast to the original requirement of taking the pills in a doctor's office followed by three check-up appointments.
• 🔒 Safeguards have been significantly loosened over time, particularly during the Obama and Biden administrations.
• ❓ Critics advocate for Mifepristone to be removed from pharmacy shelves pending a full FDA review of the EPC's study.
• 📢 The FDA spokesperson stated that the agency is reviewing incoming data and will act if a real signal is detected.